S&P 500   3,117.79 (-0.09%)
DOW   28,003.53 (0.00%)
QQQ   202.39 (-0.26%)
BABA   186.82 (+0.72%)
GE   11.38 (-1.22%)
ACB   2.49 (-9.14%)
F   8.94 (-0.11%)
BAC   32.85 (-0.24%)
DIS   148.45 (+2.61%)
S&P 500   3,117.79 (-0.09%)
DOW   28,003.53 (0.00%)
QQQ   202.39 (-0.26%)
BABA   186.82 (+0.72%)
GE   11.38 (-1.22%)
ACB   2.49 (-9.14%)
F   8.94 (-0.11%)
BAC   32.85 (-0.24%)
DIS   148.45 (+2.61%)
S&P 500   3,117.79 (-0.09%)
DOW   28,003.53 (0.00%)
QQQ   202.39 (-0.26%)
BABA   186.82 (+0.72%)
GE   11.38 (-1.22%)
ACB   2.49 (-9.14%)
F   8.94 (-0.11%)
BAC   32.85 (-0.24%)
DIS   148.45 (+2.61%)
S&P 500   3,117.79 (-0.09%)
DOW   28,003.53 (0.00%)
QQQ   202.39 (-0.26%)
BABA   186.82 (+0.72%)
GE   11.38 (-1.22%)
ACB   2.49 (-9.14%)
F   8.94 (-0.11%)
BAC   32.85 (-0.24%)
DIS   148.45 (+2.61%)
Log in

Eyepoint Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:EYPT)

-0.03 (-2.17 %)
(As of 11/18/2019 11:11 AM ET)
Today's Range
Now: $1.35
50-Day Range
MA: $2.06
52-Week Range
Now: $1.35
Volume7,902 shs
Average Volume712,470 shs
Market Capitalization$145.96 million
P/E RatioN/A
Dividend YieldN/A
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Current SymbolNASDAQ:EYPT



Sales & Book Value

Annual Sales$2.96 million
Book Value$0.15 per share


Net Income$-53,170,000.00
Net Margins-409.07%


Market Cap$145.96 million
Next Earnings Date3/12/2020 (Estimated)

Receive EYPT News and Ratings via Email

Sign-up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions

What is Eyepoint Pharmaceuticals' stock symbol?

Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

How were Eyepoint Pharmaceuticals' earnings last quarter?

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) posted its quarterly earnings results on Thursday, November, 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.01. The business earned $2.51 million during the quarter, compared to the consensus estimate of $4.81 million. Eyepoint Pharmaceuticals had a negative return on equity of 250.32% and a negative net margin of 409.07%. View Eyepoint Pharmaceuticals' Earnings History.

When is Eyepoint Pharmaceuticals' next earnings date?

Eyepoint Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Eyepoint Pharmaceuticals.

What price target have analysts set for EYPT?

4 Wall Street analysts have issued 1-year target prices for Eyepoint Pharmaceuticals' stock. Their forecasts range from $4.00 to $5.00. On average, they expect Eyepoint Pharmaceuticals' stock price to reach $4.38 in the next twelve months. This suggests a possible upside of 217.0% from the stock's current price. View Analyst Price Targets for Eyepoint Pharmaceuticals.

What is the consensus analysts' recommendation for Eyepoint Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyepoint Pharmaceuticals.

What are Wall Street analysts saying about Eyepoint Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eyepoint Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known as pSivida Corp., is headquartered in Watertown, MA. " (11/8/2019)
  • 2. HC Wainwright analysts commented, "We note that this is the first quarter that the company reports product sales after the commercial launch of YUTIQ and DEXYCU. the company launched YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg for up to three years of continuous treatment of chronic, non-infectious posterior segment uveitis. YUTIQ sales in 1Q19 were $543K based on roughly 77 units delivered to distributors. the company launched DEXYCU (dexamethasone intraocular suspension) 9% as a single dose intraocular steroid product for the treatment of post-operative ocular inflammation. DEXYCU sales in 1Q19 were $684K based on roughly 1352 units delivered to distributors. In our view, these market uptake data are impressive given the short period of time the products are available during 1Q19." (5/9/2019)

Has Eyepoint Pharmaceuticals been receiving favorable news coverage?

Press coverage about EYPT stock has trended very negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Eyepoint Pharmaceuticals earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Eyepoint Pharmaceuticals.

Are investors shorting Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals saw a increase in short interest in October. As of October 31st, there was short interest totalling 5,640,000 shares, an increase of 6.6% from the September 30th total of 5,290,000 shares. Based on an average daily volume of 472,900 shares, the short-interest ratio is currently 11.9 days. Currently, 8.8% of the company's shares are sold short. View Eyepoint Pharmaceuticals' Current Options Chain.

Who are some of Eyepoint Pharmaceuticals' key competitors?

What other stocks do shareholders of Eyepoint Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyepoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Alimera Sciences (ALIM), Exelixis (EXEL), NVIDIA (NVDA), Opko Health (OPK) and BIOLINERX LTD/S (BLRX).

Who are Eyepoint Pharmaceuticals' key executives?

Eyepoint Pharmaceuticals' management team includes the folowing people:
  • Ms. Nancy S. Lurker, Pres, CEO & Director (Age 62)
  • Mr. Leonard S. Ross, VP of Fin. & Chief Accounting Officer (Age 69)
  • Dr. Dario A. Paggiarino, VP & Chief Medical Officer (Age 62)
  • Mr. David J. Price, Chief Financial Officer (Age 56)
  • Mr. Marty Nazzaro, Sr. VP of Operations

Who are Eyepoint Pharmaceuticals' major shareholders?

Eyepoint Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Essex Investment Management Co. LLC (0.74%) and Creative Planning (0.02%). Company insiders that own Eyepoint Pharmaceuticals stock include Douglas Evan Godshall, Ew Healthcare Partners, LP, George Elston, Jay S Duker, John B Landis and Nancy Lurker. View Institutional Ownership Trends for Eyepoint Pharmaceuticals.

Which institutional investors are selling Eyepoint Pharmaceuticals stock?

EYPT stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC. View Insider Buying and Selling for Eyepoint Pharmaceuticals.

Which institutional investors are buying Eyepoint Pharmaceuticals stock?

EYPT stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have bought Eyepoint Pharmaceuticals stock in the last two years include Douglas Evan Godshall, Ew Healthcare Partners, LP, George Elston, Jay S Duker, John B Landis and Nancy Lurker. View Insider Buying and Selling for Eyepoint Pharmaceuticals.

How do I buy shares of Eyepoint Pharmaceuticals?

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eyepoint Pharmaceuticals' stock price today?

One share of EYPT stock can currently be purchased for approximately $1.38.

How big of a company is Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals has a market capitalization of $149.21 million and generates $2.96 million in revenue each year. The company earns $-53,170,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Eyepoint Pharmaceuticals employs 55 workers across the globe.View Additional Information About Eyepoint Pharmaceuticals.

What is Eyepoint Pharmaceuticals' official website?

The official website for Eyepoint Pharmaceuticals is http://eyepointpharma.com/.

How can I contact Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 833-393-7646 or via email at [email protected]

MarketBeat Community Rating for Eyepoint Pharmaceuticals (NASDAQ EYPT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  369 (Vote Outperform)
Underperform Votes:  281 (Vote Underperform)
Total Votes:  650
MarketBeat's community ratings are surveys of what our community members think about Eyepoint Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel